|Summary sheet: DPT|
|Common names||DPT, Dipropyltryptamine, "The Light"|
|Routes of Administration|
N,N-Dipropyltryptamine (also known as Dipropyltryptamine, DPT, and "The Light") is a lesser-known psychedelic substance of the tryptamine class. It is closely related to DMT and is reported to be uniquely similar in its hallucinogenic intensity, albeit with a moderately longer duration and greater unpredictability relative to DMT and other psychedelic tryptamines.
DPT was first synthesized in 1950. Human use was first reported in 1973, where it was researched in low doses as an adjunct to therapy for alcoholism. It has also been researched in high doses to induce peak experiences for terminal cancer patients. It has gained some notoriety for its adoption as the primary sacrament for the "Temple of the True Inner Light" in the United States, a Christian off-shoot organization who believe in the ritual use of psychedelics and refer to them as "the true flesh of God."
DPT is commonly consumed via insufflation or orally. Many report the experience of insufflation to be very congestive and painful which, with the rapidness of onset, does not give the user much time to acclimate themselves to its powerful effects. It can also be administered intramuscularly or via vaporization after conversion to the freebase form. Smoking the freebase is reported to be the preferred route used by the "Temple of True Inner Light". More experiences members ingest a DPT tea.
Very little data exists about the pharmacological properties, metabolism, and toxicity of DPT, and it has relatively little history of human usage. It has long been available on the research chemicals market as a legal, grey-market alternative to DMT, and commercially distributed through online vendors. Many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens. It is highly advised to approach this powerful psychedelic substance with the proper amount of precaution and harm reduction practices when using it.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 Literature
- 9 References
DPT, or N,N-dipropyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DPT contains two propyl groups carbon chains bound to the terminal amine RN of its tryptamine backbone.
The role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.
Relative to psychedelic tryptamines like DMT, DPT is often reported to be similar in its hallucinogenic intensity, albeit with a moderately longer duration and more challenging effects. DPT experiences are often described as a "bizarre", "unsettling", and "darker" version of DMT experiences. DPT is reported to be more sensual and physical than DMT and other psychedelics with a corresponding amount of adverse physical effects.
At light to moderate doses, users often report a slight sense of anaesthetization and relaxation. As the dose increases, hyper-awareness of one's heart rate and breathing increases and body tremors and loss of muscle control are often reported. The effects of DPT can range from strong euphoria and sensuality to nausea, panic, and intense states dysphoria even within the same experience.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses are more likely to induce the full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.
- Spontaneous bodily sensations - The "body high" of DPT is generally more prominent to that of the better known DMT. There is often the sensation of limbs feeling disconnected from the body, a force pinning the body to the surface on which it lay and body tremors which can often make the user feel aware of but not in control of their body.
- Physical autonomy
- Changes in felt bodily form
- Changes in felt gravity - At higher doses, physical feelings of moving through spaces at quick speeds or being completely pinned down are common.
- Abnormal heartbeat
- Increased blood pressure
- Motor control loss
- Muscle contractions
- Excessive yawning
- Pupil dilation
- Increased libido - This effect appears to occur with more regularity and intensity than other psychedelic tryptamines.
- Drifting (melting, breathing, morphing and flowing)
- After images
- Colour replacement
- Colour shifting
- Environmental patterning
- Scenery slicing
- Symmetrical texture repetition
- Visual haze
DPT visual geometry can be described through its variations as intricate in complexity, both abstract and concrete in form, more digital than organic in feel, choppy and only loosely structured in organization, brightly lit, multicolored in scheme, sharp in its edges, fast in speed, simultaneously smooth and glitching in motion, immersive in depth, and consistent in intensity. At higher doses, it is more likely to result in states of level 8A geometry over level 8B.
DPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic barring DMT and ibogaine. These effects include:
- Machinescapes - These are reported to be more common with DPT than with DMT, which lends to its common description as feeling more "industrial" and futuristic, while DMT visuals can often be described as "ancient" or "earthy" in feel.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - As with DMT, DPT produces high level internal hallucinations at appropriate doses more consistently than most other psychedelics. They are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and typically of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.
- Anxiety & Paranoia
- Conceptual thinking
- Cognitive euphoria & Cognitive dysphoria
- Déjà vu
- Emotionality enhancement
- Feelings of impending doom
- Increased music appreciation
- Increased sense of humor
- Novelty enhancement
- Immersion enhancement
- Personal meaning enhancement
- Memory suppression
- Language suppression
- Personal bias suppression
- Simultaneous emotions
- Spatial disorientation
- Autonomous voice communication
- Multiple thought streams
- Thought disorganization
- Thought loops
- Time distortion
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
- Many reports indicate that while DPT possesses the raw hallucinogenic power to induce transpersonal states traditionally associated with "classical psychedelics", it does so in a significantly less consistent fashion due to the utter bizarreness and oft-noted "sinister", chaotic, or "forceful" undertones that can be present throughout the experience. What insights it can lead the user to typically occur during the aftermath and integration phase that follows, which shares some qualities of a typical near-death experience.
Anecdotal reports which describe the effects of this compound within our experience index include:
- Experience: Oral & Insufflated DPT, Running up the Doses
- Experience:10mg & 20mg Intravenous DPT HCl - Familiar Shapes, Experiencing Death, Immersed in The Light
- Experience:150mg DPT - A Walk Into The Depths of Insanity
- Experience:75 mg - Good tunes feat. Jeb Bush
Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
The toxicity and long-term health effects of recreational DPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because DPT is a research chemical with very little history of human usage.
Anecdotal reports from those who have taken DPT suggests that negative health effects are not likely to occur from simply trying it by itself at low to moderate doses and using it very sparingly (although nothing can be guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
DPT is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is reported to be self-limiting.
Tolerance to the effects of DPT have been shown to not be built in animal models. However, it has been reported to be able to build slightly relative to DMT, although still to an insignificant degree compared to most psychedelics.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Tramadol - Tramadol lowers the seizure threshold and LSD also has the potential to induce seizures in susceptible individuals. and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
- Germany: DPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Latvia: DPT is a Schedule I controlled substance.
- New Zealand: DPT is an analogue of DMT, so is a Class C controlled substance in New Zealand.
- Sweden: Following its sale as a designer drug, DPT was made illegal in Sweden on January 26, 2016.
- Switzerland: DPT is a controlled substance specifically named under Verzeichnis E.
- United Kingdom: DPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: DPT is unscheduled in the United States. It may be considered an analogue of DET, a Schedule I controlled substance under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act. DPT is a Schedule I controlled substance in the states of Florida, Maine, and Oklahoma making it illegal to buy, sell, or possess.
- Soskin, R.A., Grof, S., & Richards, W.A. (1973). Low doses of Dipropyltryptamine in psychotherapy. Archives of General Psychiatry, 28 6, 817-21.
- Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen, R., & Kurland, A. A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9(1), 1-10. http://dx.doi.org/10.1080/02791072.1977.10472020
- Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1972). DPT as an adjunct in psychotherapy of alcoholics. International Pharmacopsychiatry, 8(1), 104-115. PMID: 4150711
- Li, J., Rice, K.C., & France, C.P. (2007). Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity. Behavioural Pharmacology, 18 4, 283-8.
- Li, J. X.; Rice, K.; France, C. P. (2007). "Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity". Behavioural Pharmacology. 18 (4): 283–288. doi:10.1097/FBP.0b013e3281f19ca0. eISSN 1473-5849. ISSN 0955-8810. OCLC 22170289. PMID 17551320.
- Grof, S.; Soskin, R. A.; Richards, W. A.; Kurland, A. A. (1973). "DPT as an Adjunct in Psychotherapy of Alcoholics". International Pharmacopsychiatry. 8 (1): 104–115. doi:10.1159/000467979. ISSN 0020-8272. OCLC 1753673. PMID 4150711.
- Richards, W. A.; Rhead, J. C.; Dileo, F. B.; Yensen, R.; Kurland, A. A. (1977). "The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients". Journal of Psychedelic Drugs. 9 (1): 1–10. doi:10.1080/02791072.1977.10472020. ISSN 0022-393X. OCLC 7565359.
- "Temple of the True Inner Light". Retrieved January 9, 2020.
- Fantegrossi, W. E.; Reissig, C. J.; Katz, E. B.; Yarosh, H. L.; Rice, K. C.; Winter, J. C. "Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents". Pharmacology Biochemistry and Behavior. 88 (3): 358–365. doi:10.1016/j.pbb.2007.09.007. ISSN 0091-3057. OCLC 848182005. PMC . PMID 17905422.
- Smith, D. A.; Bailey, J. M.; Williams, D.; Fantegrossi, W. E. (2014). "Tolerance and Cross-Tolerance to Head Twitch Behavior Elicited by Phenethylamine- and Tryptamine-Derived Hallucinogens in Mice". Journal of Pharmacology and Experimental Therapeutics. 351 (2): 485–491. doi:10.1124/jpet.114.219337. eISSN 1521-0103. ISSN 0022-3565. OCLC 1606914. PMC . PMID 25271256.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. PMC . PMID 19415589.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- "Title XLVI: Chapter 893: Drug Abuse Prevention And Control". The 2019 Florida Statutes. The Florida Legislature. Retrieved January 10, 2020.
- "Section 2-204 - Schedule I". Oklahoma Statutes Citationized. Oklahoma Judicial Center. January 11, 2019. Archived from the original on July 9, 2019. Retrieved January 10, 2020.